Pharmaceutical/Biotechnology - Clinical-Stage Cannabinoid and Psychedelic Therapeutics
Strategic Profile
Through NeuroThera Labs, the company reports progress on cannabinoid-based drug candidates, patent grants, and collaborations targeting central nervous system and neuropsychiatric disorders. Recent corporate transactions include the transfer of its advanced clinical-stage pharmaceutical portfolio to NeuroThera Labs and the sale of its oncology-focused subsidiary MitoCareX Bio Ltd.
Cyborg Score Rationale
SciSparc has trailing twelve months net income of negative $3.5M. The company received notification that it is not in compliance with the minimum stockholders' equity requirement, having reported approximately negative $81,000 in stockholders' equity as of June 30, 2025. Stock performance has deteriorated significantly with ongoing Nasdaq compliance challenges.
Top Insights
Drug development programs include SCI-110 for Tourette syndrome and Alzheimer's disease/agitation, and SCI-210 for autism spectrum disorder and status epilepticus
Company announced quantum computing-enabled 3D protein modeling initiative for drug discovery and a non-binding term sheet for NeuroThera to acquire majority stake in quantum bio data analysis company
NeuroThera Labs signed definitive agreement to acquire ~54% of CliniQuantum, a quantum technology company, issuing 56.6M shares valued at ~$9.46M with up to $2.5M earnouts, closing expected March 31, 2026
NeuroThera Labs received Israeli patent for proprietary opioid and N-acylethanolamines combination designed to reduce pain medication side effects
Named Competitors
Clearmind Medicine — Psychedelic-derived therapeutics for mental health
Revelation Biosciences — Immunotherapy and biotech innovation
Compass Pathways — Psychedelic-assisted therapies
atai Life Sciences — Mental health and psychedelic treatments
Recent Developments
(March 2026) Reverse 1-for-9 share split effective March 4, 2026; CliniQuantum acquisition expected to close
(December 2025) AutoMax Motors announced first delivery of JAC vehicles following regulatory approval
(November 2025) Registered direct offering and debenture conversion of $4.2M in August 2025 to address stockholders' equity compliance
(August 2025) Multiple announcements on patent filings and research collaborations with Clearmind Medicine on psychedelic combination therapies
Open the full interactive SciSparc Ltd. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.